A trace inequality for loxodromics of length β€ 2 in free kleinian groups
2025
0 views
0 downloads
Advisor: Dr. ΓΔr. Γyesi Δ°lker SavaΕ YΓΌce
Abstract (EN)
Let Ξ = β¨π,πβ© denote a purely loxodromic free Kleinian group. For any πΎ βΞ and any π§ in the hyperbolic 3-space H3, let dist(π§,πΎ(π§))denote the hyperbolic distance between π§ and the image πΎ(π§) of π§ under πΎ. Let Ξ¨2 = {πΎ βΞ : β(πΎ) β€2}, where β(πΎ) denotes the length of πΎ as a reduced word in Ξ. Firstly, in this thesis, it is proved that max{dist(π§,πΎ(π§)) : πΎ βΞ¨π6}β₯3.36611... for any π§βH^3 forΞ¨_6^π = {πππβ1 : π,π βΞ¨_2}. Secondly, as a consequence, it is shown that a version of the JΓΈrgensen's inequality expressed as |trace^2(π_0)β4|+|trace2(π_0^(-1)π_0π_0^(β1)π_0^(β1))β2|β₯13.5 is satisfied for some distinct π_0,π_0 βΞ¨^2 assuming the inequalities dist(π§_2,π_0π_0π_0^(β1)(π§_2)) β€dist(π§_1,π_0π_0π_0^(β1)(π§1)) and dist(π§_2,πΎ(π§_2)) <3.36611... holdforeveryπΎ βΞ¨π6 β{π0,πβ10 ,πβ10 π0π0,πβ10 πβ10 π0,π0π0πβ10 ,π0πβ10 πβ10 }. Above, π§_1 and π§_2 are the midpoints of the shortest geodesic segments connecting the axis of π_0 to the axes of π_0π_0π_0^(β1) and π_0^(β1)π_0π_0, respectively.
Author
Γmer Volkan CΓΌran
How to Cite
Γmer Volkan CΓΌran (Doctorate thesis). A trace inequality for loxodromics of length β€ 2 in free kleinian groups, 2025, Yeditepe University.
Keywords
License
TΓΌm HaklarΔ± SaklΔ±dΔ±r
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)